Venus Remedies (VRL) will be launching its third research product focussed on the treatment of life-threatening infections caused by multi-drug resistant (MDR) P.aeruginosa or acinetobacter bacteria species in 48 countries globally.VRL has completed patent filing in these countries. The product was launched in India in October 2006 and is fast growing to be one of the leading multi-specialty, critical care brands. The potential market for this product across the globe is estimated to be around $1 billion.VRL has filed the patent under the national phase of PCT application for worldwide protection of the innovation in Patent 3 that is "fixed dose combination of a latest generation cephalosporin with an aminoglycoside".The Indian Patent was filed in December 2004 and the PCT in December 2005. The company selected 48 countries with good market potential in the national phase of the PCT application for global patent, including entire Europe, USA, Brazil, Japan, Canada, Australia and New Zealand, where it would be registering and launching this product.
